Smoking CessationNCT06943287
Pharmacist Intervention to Improve Smoking Cessation
A study testing Pharmacist Intervention in people with Smoking Cessation, run by University of Iowa at 1 site in United States.
Trial summary
The goal of this study is to assess the effectiveness of a remote pharmacist intervention to help smokers quit. The main questions it aims to answer are: Will smokers being screened for lung cancer with low-radiation-level chest computed tomography (CT) be willing to participate in this study and talk to the… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Smoking Cessation
- What is being tested?
- Pharmacist Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Aug 2025to 6 Jul 2026
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Current smoker
- Current patient in the Lung Cancer Screening Program
Who cannot join
- Unable to speak/read English
- Unable to provide their own written informed consent
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Iowa Health Care
Iowa City, Iowa, 52242
About this study
Official title: A Remote Pharmacist Intervention to Improve Smoking Cessation
The goal of this study is to assess the effectiveness of a remote pharmacist intervention to help smokers quit.
The main questions it aims to answer are:
Read more
- Will smokers being screened for lung cancer with low-radiation-level chest computed tomography (CT) be willing to participate in this study and talk to the pharmacist about smoking cessation?
- Will those in the intervention group be more likely to report smoking cessation than those in the control group.
Participants in the intervention group will be asked to complete a baseline survey; speak with a pharmacist via phone call at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks; and complete an exit survey.
Participants in the control group will be asked to complete a baseline survey and an exit survey.
- Conditions
- Smoking Cessation
- Being tested
- Pharmacist Intervention
- Medical subject headings
- Smoking Cessation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pharmacist InterventionBehavioural
If the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Pharmacist Intervention Group | Experimental | Not described Receives: Behavioral: Pharmacist Intervention |
| Control Group | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Interactions With Pharmacist
The number of phone calls the intervention participants complete with the research pharmacist.
Measured: 12 weeks
Secondary outcomes (3)
Number of Nicotine Replacement Therapies Used to Quit Smoking
The number of participants who use nicotine replacement therapies during the study.
Measured: 12 weeks
Number of Non-Medication Tools Used to Quit Smoking
The number of participants who use non-medication tools to quit smoking.
Measured: 12 weeks
Number of Successful Quit Attempts
The number of participants who have successfully quit smoking at the end of the study.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2025
- Study start11 Aug 2025
- Primary completion6 Jul 2026
- Study completion6 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- More trials run by University of IowaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Iowa
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jacob E. Simmering, University of Iowa
- Investigators
- Jacob E Simmering, PhD, Principal investigator, University of Iowa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06943287
- Sponsor's protocol ID
- 202411248
- Status last verified
- Jul 2026
- First submitted
- 16 Apr 2025
- Last updated
- 31 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Remote Pharmacist Intervention to Improve Smoking Cessation
- ClinicalTrials.gov ID
- NCT06943287
- Acronym / sponsor ID
- 202411248
- Conditions
- Smoking Cessation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- University of IowaUniversity, hospital or other
- Study start
- 11 Aug 2025 (actual)
- Primary completion
- 6 Jul 2026 (actual)
- Study completion
- 6 Jul 2026 (actual)
- First posted
- 24 Apr 2025 (actual)
- Results
- Posted 31 Aug 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to assess the effectiveness of a remote pharmacist intervention to help smokers quit.
The main questions it aims to answer are:
- Will smokers being screened for lung cancer with low-radiation-level chest computed tomography (CT) be willing to participate in this study and talk to the pharmacist about smoking cessation?
- Will those in the intervention group be more likely to report smoking cessation than those in the control group.
Participants in the intervention group will be asked to complete a baseline survey; speak with a pharmacist via phone call at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks; and complete an exit survey.
Participants in the control group will be asked to complete a baseline survey and an exit survey.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pharmacist Intervention Group | Experimental | Behavioral: Pharmacist Intervention |
| Control Group | No intervention | – |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Current smoker
- Current patient in the Lung Cancer Screening Program
Key exclusion criteria (2 listed)
- Unable to speak/read English
- Unable to provide their own written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pharmacist InterventionIf the patient is randomized to the intervention group, they will complete a series of phone calls with the research pharmacist. These will occur at baseline (within 1 to 2 days of enrollment), 2-weeks, 4-weeks, 6-weeks, 8-weeks, 10-weeks, and 12-weeks. During these calls, the research pharmacist will ask the patient about any past quit attempts; when they had their last cigarette; if they have been prescribed any cessation medications; if they have picked up their medication; if they have started the medication; they will assess their stage of change for quitting; discuss pros, cons, and barriers of quitting; behavioral responses to triggers/urges; and make any necessary nicotine replacement therapy (NRT; i.e., nicotine patches, gums, lozenges, inhalers, and/or nasal sprays) changes. Each call is expected to take 20-30 minutes. | Behavioural | Pharmacist Intervention Group |
Primary outcome
Number of Interactions With Pharmacist
Time frame: 12 weeks
The number of phone calls the intervention participants complete with the research pharmacist.
3 secondary outcomes
Number of Nicotine Replacement Therapies Used to Quit Smoking
Time frame: 12 weeks
Number of Non-Medication Tools Used to Quit Smoking
Time frame: 12 weeks
Number of Successful Quit Attempts
Time frame: 12 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Smoking Cessation
Active, not recruiting
An Interactive Smartphone Application to Motivate Smokers to Quit
Smoking Cessation, Smoking Behaviors
Not yet recruiting
Comparing the Efficacy of a Conversational Agent (QuitBot) Versus Standard Health Education on Smoking Cessation Among Medical Students; A Randomized Controlled Trial.
Conversational Agent, Smoking Cessation
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Active, not recruitingPhase 3
Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation
Tobacco Dependence
Active, not recruitingEarly Phase 1
Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer
Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jacob E Simmering, PhD principal investigator
University of Iowa
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pharmacist Intervention in people with Smoking Cessation, run by University of Iowa at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 31 Aug 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Interactions With Pharmacist (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.